![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
X
20
Astellas Pharma Inc. Tokyo Jp, based in Japan, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their significant offerings is Cefixime, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 1999-158 - Rev 01
This Chemical Type CEP, issued on April 04, 2007, remains in force until October 12, 2023, ensuring its reliability within the pharmaceutical industry.
Substance Number 1188 associated with this CEP further emphasizes